Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Association of serum 25-hydroxyvitamin D with urinary albumin-to-creatinine ratio and diabetic retinopathy in hospitalized patients with type 2 diabetes mellitus: a cross-sectional study.

BMC endocrine disorders·2026

Same author

Green synthesis of nisin-loaded pectin based silver nanoparticles and their antimicrobial and biosafety assessment.

Discover nano·2026

Same author

A U-shaped association between vitamin D and ketone levels in type 2 diabetes: a metabolic state-dependent dual regulation mechanism.

Diabetology & metabolic syndrome·2026

Same author

Thermally-driven bacterial mechanism of biogenic amines enrichment in central pile-fermentation zones of Liuyang Douchi.

Food chemistry: X·2025

Same author

Robotic assistance for skull base biopsy: a feasibility study in phantom and cadaver.

Frontiers in oncology·2025

Same author

S-nitrosoglutathione inhibits pyroptosis of kidney tubular epithelial cells in sepsis via the SIRT3/SOD2/mtROS signaling pathway.

Renal failure·2025

Search research articles

Related Experiment Video

Updated: May 29, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

[Advanced dermatofibrosarcoma protuberans treated with imatinib mesylate].

Jian-hua Zhu¹, Qiu-wen Li, Wen-hua Xiao

¹Department of Chemotherapy, the First Affiliated Hospital of People's Liberation Army General Hospital, Beijing 100048, China. zjhua168@sohu.com

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]

|August 31, 2011

Summary

Imatinib mesylate shows significant efficacy in treating advanced dermatofibrosarcoma protuberans (DFSP), with a high disease control rate and manageable side effects. This molecularly targeted drug is a valuable option for patients with advanced DFSP.

More Related Videos

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Experiment Videos

Last Updated: May 29, 2026

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib

Published on: April 3, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Area of Science:

Oncology
Dermatology
Pharmacology

Background:

Dermatofibrosarcoma protuberans (DFSP) is a rare malignant skin tumor.
Advanced and/or metastatic DFSP presents a significant treatment challenge.
Limited effective systemic therapies exist for advanced DFSP.

Purpose of the Study:

To assess the efficacy of imatinib mesylate in patients with advanced or metastatic DFSP.
To evaluate the safety profile, including side effects and toxicity, of imatinib mesylate treatment.
To determine the impact of imatinib mesylate on survival outcomes in DFSP patients.

Main Methods:

A retrospective study of 24 advanced DFSP patients treated with imatinib mesylate (400 mg daily).
Patients received imatinib as second-line (2 patients) or third/later-line (22 patients) therapy.
Efficacy, side effects, and survival time were meticulously monitored.

Main Results:

A high overall response rate was observed: 33.3% complete response (CR), 41.7% partial response (PR).
The disease control rate (CR+PR+SD) was 83.3%, with a median survival of 30 months for responders.
Common side effects included nausea/vomiting (20.8%), neutropenia (12.5%), and edema (8.3%), generally mild.

Conclusions:

Imatinib mesylate demonstrates significant efficacy and a favorable safety profile in treating advanced DFSP.
The drug achieved a high disease control rate and prolonged survival in this patient cohort.
Imatinib is confirmed as a safe and effective molecularly targeted therapy for advanced DFSP.